Luspatercept Reduces Dependence on Blood Transfusions in Patients With MDS

Treatment with luspatercept (Reblozyl, Bristol Myers Squibb) led to significant improvements in red blood cell (RBC) counts and erythroid responses compared with treatment with epoetin alfa in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the phase 3 COMMANDS trial, allowing many to avoid the need for regular blood transfusions. The interim results, reported at the 2023 American Society of Clinical Oncology annual meeting (abstract 7003), are the first to show the superiority